

Atty Dkt No. 9001-0034.21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECORDATION COVER SHEET (PATENT)

1. Name of conveying party/parties:  
  
Biostar Inc.
2. Name and address of receiving party/parties:  
  
MetaMorphix International, Inc.  
1450 South Rolling Road  
Baltimore, Maryland 21227
3. Nature of conveyance:  

X

—

—

Assignment  
Name Change  
Other

Execution date: August 15, 2000

4. Application number(s) or patent number(s):  
  
A. Patent Application No(s).: 08/952,568 (now USP 6,037,321)  
  
B. Patent No(s).: 6,037,321

If this document is being filed together with a new application, the execution date of the application is:  
and the title of the new application is:

5. Name and address of party to whom correspondence concerning document should be mailed:  
  
Roberta L. Robins  
ROBINS & PASTERNAK LLP  
90 Middlefield Road, Suite 200  
Menlo Park, CA 94025

6. Total number of applications/patents involved: 1

7.     Total fee:   1   x \$40.00 = \$ 40.00

         Enclosed is a check for \$ 40.00.

 X      Authorized to be charged to deposit account


8.     Deposit account number: 18-1648.

9.     The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

10.    Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Dated:   2/11/02  

By:   
Roberta L. Robins  
Reg. No. 33,208

ROBINS & PASTERNAK LLP  
90 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 325-7812  
Fax: (650) 325-7823

**Total number of pages including cover sheet, attachments, document: 8**

Mail to:    U.S. Patent and Trademark Office  
            Office of Public Records, Box Assignment  
            Crystal Gateway 4, Room 335  
            Washington, D.C. 20231

**PATENT ASSIGNMENT - SOLE****FOR VALUE RECEIVED:**

1. **Biostar Inc.** (the "Assignor"), the owner of the patents identified in the attached Schedule "A" (the "Patents") hereby unconditionally assigns, transfers, and sets over to and unto **MetaMorphix International, Inc.**, having its principal office or place of business at 1450 South Rolling Road, Baltimore, Maryland, United States of America, 21227, (the "Assignee"), its entire right, title and interest in and to the Patents, wherever registered, and any and all Letters Patent(s) in the United States which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said applications or reissues or extensions of said Letters Patents, together with the entire goodwill attached thereto, all to be held and enjoyed by the Assignee, its successors and assigns, as fully and completely as by the Assignor had this assignment not been made.
2. The Assignor hereby authorizes and requests the Patent Office Officials in Canada, the United States and its territorial possessions, and any and all foreign countries to issue any and all of said Letters Patents, when granted, to said Assignee as the assignee of the entire right, title and interest in and to the same.
3. Further, the Assignor agrees that it will communicate to said Assignee or its representatives any facts known respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, substitute, renewal and reissue applications, execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to said Assignee, make all rightful oaths, and, generally perform all reasonable acts possible to aid said Assignee, its successors and assigns, to obtain and enforce proper protection for said invention in Canada, the United States and its territorial possessions, and in any and all foreign countries, at the expense of the Assignees.

Dated at Saskatoon, Saskatchewan, Canada this 15<sup>th</sup> day of August, 2000.

**METAMORPHIX INTERNATIONAL, INC.**

By: 

Edwin C. Quattlebaum, Ph.D.  
President & CEO

**BIOSTAR INC.**

By: 

Stephen D. Acres, DVM, MPVM, Ph.D.  
President and CEO

By: 

Todd L. Lahti  
Vice-President and Chief Financial Officer

1. THAT Stephen Acres, DVM, MPVM, Ph.D. is personally known to me and that he is the President and Chief Executive Officer of Biostar Inc., a Canadian corporation;
2. THAT Stephen Acres, DVM, MPVM, Ph.D. has signing authority to assign and convey assets on behalf of Biostar Inc.
3. THAT Stephen Acres, DVM, MPVM, Ph.D. signed the attached document as his voluntary act for the purposes therein set forth.

August, 1968

My Commission expires \_\_\_\_\_, 20\_\_

### \*Being a Solicitor


Jeffrey F. Vico



AFFIDAVIT

I, JEFFREY F. VICQ, of the City of Saskatoon, in the Province of Saskatchewan, in the Dominion of Canada, Barrister and Solicitor, MAKE OATH AND SAY AS FOLLOWS:

- 1. THAT Todd L. Lahti is personally known to me and that he is the Vice President, Chief Financial Officer and Secretary of Biostar Inc., a Canadian corporation;
- 2. THAT Todd L. Lahti has signing authority to assign and convey assets on behalf of Biostar Inc.
- 3. THAT Todd L. Lahti signed the attached document as his voluntary act for the purposes therein set forth.

SWORN before me at the City of )  
Saskatoon, in the Province of )  
Saskatchewan, this 15<sup>th</sup> day of )  
August, 2000. )

  
Jeffrey F. Vicq


  
A Commissioner for Oaths in and  
for the Province of Saskatchewan.  
~~My Commission expires~~ 20  
Being a Solicitor 

**AFFIDAVIT**


I, SHERYL N. STEPHENSON, of the City of Baltimore, in the State of Maryland, in the United States of America, Attorney-at-Law. MAKE OATH AND SAY AS FOLLOWS:

1. THAT Edwin C. Qualtlebaum Ph.D. is personally known to me and that he is the President of MMI International, Inc., a Delaware corporation;
2. THAT Edwin C. Qualtlebaum Ph.D. has signing authority to assign and convey assets on behalf of MMI International, Inc.
3. THAT Edwin C. Qualtlebaum Ph.D. signed the attached document as his voluntary act for the purposes therein set forth.

SWORN before me at the City of  
Saskatoon, in the Province of  
Saskatchewan, this 15<sup>th</sup> day of  
August, 2000.

  
A Commissioner for Oaths in and  
for the Province of Saskatchewan.

My Commission expires                     , 20          

Being a Solicitor 

  
Sheryl N. Stephenson

**SCHEDULE "A"**

Technology Platform or Product Area	Patent Status
<b>1. Delivery of Immunosterilant Products to Animals – two applications pending</b>  1.1 "Pharmaceutical Delivery System" (Matter #9001-0033) <sup>A</sup>  1.2 "Immunization Against Endogenous Molecules" (Matter #9001-0035)	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 09/009,068</li> <li>• U.S. Patent Application No. - 09/019,010</li> </ul>
<b>2. Production, Formulation and Use of Immunosterilant Products (e.g. human, porcine, bovine, feline, canine)</b>  2.1 "GnRH Immunization in Prepubertal Animals" or "Methods for Suppressing Reproductive Behaviour in Animals" (Matter #9001-0047)  2.2 "Methods of Raising Animals for Meat Production" (Matter #9001-0048)  2.4 "The Use of Ultrasonography To Evaluate Size and Echotexture of Gonadal and Accessory Genital Structures in Domestic Animals" (Matter #76059-6)	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 09/306,689</li> <li>• U.S. Patent Application No. - 09/305,924</li> <li>• Issued – U.S. Patent No. - 5,705,749</li> </ul>
<b>3. "Immunological Methods to Modulate Myostatin in Vertebrate Subjects" (Matter #9001-0042)</b>	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 60/075,213</li> </ul>
<b>4. Ova-Max™</b> 3.1 "Vasoactive Intestinal Peptide" (Robins Matter #9001-0034 and Smart & Biggar Matter #76059)	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 08/952,568 - 09/444,251</li> </ul>

<sup>A</sup> Patent attorney file number.

**SCHEDULE 1.1(vi)**  
**INTELLECTUAL PROPERTY**

**A. BIOSTAR Patents**

Technology Platform or Product Area	Patent Status <sup>a</sup>	Assignment
<b>1. Delivery of Immunosterilant Products to Animals – two applications pending</b> 1.1 "Pharmaceutical Delivery System" (Matter #9001-0033) <sup>a</sup>  1.2 "Immunization Against Endogenous Molecules" (Matter #9001-0035)	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 09/009,068</li> <li>• U.S. Patent Application No. - 09/019,010</li> </ul>	Fully assigned <sup>a</sup>  Fully assigned <sup>a</sup>
<b>2. Production, Formulation and Use of Immunosterilant Products (e.g. human, porcine, bovine, feline, canine)</b>  2.1 "GnRH Immunization in Prepubertal Animals" or "Methods for Suppressing Reproductive Behaviour in Animals" (Matter #9001-0047)  2.2 "Methods of Raising Animals for Meat Production" (Matter #9001-0048)  2.3 "Passive Immunization as a Treatment For Hormone Dependent Disorders" (Matter #9001-0045)  2.4 "The Use of Ultrasonography To Evaluate Size and Echotexture of Gonadal and Accessory Genital Structures in Domestic Animals" (Matter #76059-6)	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 09/306,689</li> <li>• U.S. Patent Application No. - 09/305,924</li> <li>• U.S. Patent Application No. - 09/249,447</li> <li>• Issued – U.S. Patent No. - 5,705,749</li> </ul>	Fully assigned <sup>a</sup>  Fully assigned <sup>a</sup>  Partially assigned <sup>c</sup>  Fully assigned <sup>a</sup>
<b>3. "Immunological Methods to Modulate Myostatin in Vertebrate Subjects" (Matter #9001-0042)</b>	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 60/075,213</li> </ul>	Fully assigned <sup>a</sup>
<b>4. Ova-Max<sup>TM</sup></b> 4.1 "Vasoactive Intestinal Peptide" (Robins Matter #9001-0034 and Smart & Biggar Matter #76059)	<ul style="list-style-type: none"> <li>• U.S. Patent Application No. - 08/952,568</li> <li>• 09/444,251</li> </ul>	Fully assigned <sup>a</sup>

<sup>a</sup> Patent attorney file number.

<sup>b</sup> Assignment is full to MetaMorphix

<sup>c</sup> Co-ownership of patent by BIOSTAR and MetaMorphix through partial assignment.

<sup>d</sup> All pending foreign applications and issued patents corresponding to the aforementioned U.S. applications and patents are also included as acquired assets.